Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 5/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17596207 | 0.76 | MAP4K4 (0.37) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL19784976 | 0.76 | GPR119 (0.38) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL17596209 | 0.76 | MAP4K4 (0.37) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL17926262 | 0.76 | MAP4K4 (0.39) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL17936822 | 0.76 | MAP4K4 (0.39) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL17936828 | 0.76 | MAP4K4 (0.39) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL5765341 | 0.74 | NR1H2 (0.49) | GPR119 | |
| SCHEMBL21058315 | 0.74 | GPR119 (0.38) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL19632326 | 0.74 | GPR119 (0.38) | GPR119MAP4K4SPRHDAC1SETD7 | |
| SCHEMBL34469336 | 0.73 | GPR119 (0.38) | GPR119MAP4K4HDAC1SETD7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT INC (US) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | PDE6D, PDE6H, ADRA1D | GPR119 904/4885MAP4K4 2227/4885SPR 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.